Canaccord Genuity Reiterates Hold on Biomarin Pharmaceutical, Maintains $91 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Whitney Ijem has reiterated a 'Hold' rating on Biomarin Pharmaceutical (NASDAQ:BMRN) and maintained a price target of $91.

February 29, 2024 | 3:33 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Canaccord Genuity maintains a 'Hold' rating and a $91 price target for Biomarin Pharmaceutical.
The reiteration of the 'Hold' rating and maintenance of the price target by a reputable analyst like Whitney Ijem from Canaccord Genuity suggests a neutral short-term impact on BMRN's stock price. The analyst's view likely reflects a balanced outlook on the company's current valuation and future prospects, without significant new information that would drive the stock price up or down in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100